Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age ...

Belite Bio, Inc (NASDAQ:BLTE – Free Report) – Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Belite Bio in a report issued on Wednesday, January 29th.

Belite Bio, Inc (NASDAQ:BLTE) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Belite Bio, Inc, a clinical stage biopharmaceutical ...

View Our Latest Report on BLTE Belite Bio Stock Down 1.2 % Shares of NASDAQ BLTE opened at $58.20 on Wednesday. Belite Bio has a fifty-two week low of $31.00 and a fifty-two week high of $86.53 ...

Belite Bio Incorporation American Depository Receipt Repr 1 Sh News More News Historical Prices for Belite Bio Incorporation American Depository Receipt Repr 1 Sh Belite Bio Incorporation American ...